Combination of alpha-interferon 2a (alpha-IFN 2a) and 13-cis-retinoic acid (13cRA) in recurrent, pre-treated squamous-cell carcinoma of head and neck (SCCHN)

Int J Cancer. 1997 Feb 7;70(4):491-3. doi: 10.1002/(sici)1097-0215(19970207)70:4<491::aid-ijc23>3.0.co;2-h.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Female
  • Head and Neck Neoplasms / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Isotretinoin / administration & dosage
  • Male
  • Middle Aged
  • Recombinant Proteins

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Isotretinoin